Cargando…
Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients
Cumulating reports suggest that acute phase proteins (APPs) have diagnostic and prognostic value in different clinical conditions. Among others, APPs are proposed to serve as markers that help to control the outcome of transplant recipients. Here, we questioned whether plasma concentrations of APPs...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721309/ https://www.ncbi.nlm.nih.gov/pubmed/33299339 http://dx.doi.org/10.2147/JIR.S272662 |
_version_ | 1783620012751192064 |
---|---|
author | Janciauskiene, Sabina Royer, Pierre-Joseph Fuge, Jan Wrenger, Sabine Chorostowska-Wynimko, Joanna Falk, Christine Welte, Tobias Reynaud-Gaubert, Martine Roux, Antoine Tissot, Adrien Magnan, Antoine |
author_facet | Janciauskiene, Sabina Royer, Pierre-Joseph Fuge, Jan Wrenger, Sabine Chorostowska-Wynimko, Joanna Falk, Christine Welte, Tobias Reynaud-Gaubert, Martine Roux, Antoine Tissot, Adrien Magnan, Antoine |
author_sort | Janciauskiene, Sabina |
collection | PubMed |
description | Cumulating reports suggest that acute phase proteins (APPs) have diagnostic and prognostic value in different clinical conditions. Among others, APPs are proposed to serve as markers that help to control the outcome of transplant recipients. Here, we questioned whether plasma concentrations of APPs mirror the development of chronic lung allograft dysfunction (CLAD). We performed blinded analysis of serial plasma samples retrospectively collected from 35 lung transplanted patients, of whom 25 developed CLAD and 10 remained stable during the follow-up period of 3 to 4.5 years. Albumin (ALB), alpha1-antitrypsin (AAT), high sensitivity C-reactive protein (CRPH), antithrombin-3 (AT3), ceruloplasmin (CER), and alpha2-macroglobulin (A2MG) were measured by the nephelometric method. We found that within the first six months post-transplantation, levels of A2MG, CER and AAT were higher in stable patients relative to those who later developed CLAD. Moreover, in stable patient’s plasma CRPH levels decreased during the follow-up period whereas opposite, in those developing CLAD, the CRPH gradually increased. The ALB levels became significantly lower at the end of the follow-up period in CLAD relative to a stable group. A logistic regression model based on A2MG, CER and AT3 at cut-offs levels of ≥175.5 mg/dL, ≥37.8 mg/dL and ≥27.35 mg/dL enabled to discriminate between stable and CLAD patients with a sensitivity of 87.5%, 100% and 62.5%, and specificity of 65.9%, 72.7% and 79.5%, respectively. We identified A2MG (below 175.5 mg/dL) as an independent predictor of CLAD (hazard ratio 11.5, 95% CI (1.5–91.3), p<0.021). Our findings suggest that profiles of certain APPs may help to predict the development of lung dysfunction at the very early stages after transplantation. |
format | Online Article Text |
id | pubmed-7721309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77213092020-12-08 Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients Janciauskiene, Sabina Royer, Pierre-Joseph Fuge, Jan Wrenger, Sabine Chorostowska-Wynimko, Joanna Falk, Christine Welte, Tobias Reynaud-Gaubert, Martine Roux, Antoine Tissot, Adrien Magnan, Antoine J Inflamm Res Clinical Trial Report Cumulating reports suggest that acute phase proteins (APPs) have diagnostic and prognostic value in different clinical conditions. Among others, APPs are proposed to serve as markers that help to control the outcome of transplant recipients. Here, we questioned whether plasma concentrations of APPs mirror the development of chronic lung allograft dysfunction (CLAD). We performed blinded analysis of serial plasma samples retrospectively collected from 35 lung transplanted patients, of whom 25 developed CLAD and 10 remained stable during the follow-up period of 3 to 4.5 years. Albumin (ALB), alpha1-antitrypsin (AAT), high sensitivity C-reactive protein (CRPH), antithrombin-3 (AT3), ceruloplasmin (CER), and alpha2-macroglobulin (A2MG) were measured by the nephelometric method. We found that within the first six months post-transplantation, levels of A2MG, CER and AAT were higher in stable patients relative to those who later developed CLAD. Moreover, in stable patient’s plasma CRPH levels decreased during the follow-up period whereas opposite, in those developing CLAD, the CRPH gradually increased. The ALB levels became significantly lower at the end of the follow-up period in CLAD relative to a stable group. A logistic regression model based on A2MG, CER and AT3 at cut-offs levels of ≥175.5 mg/dL, ≥37.8 mg/dL and ≥27.35 mg/dL enabled to discriminate between stable and CLAD patients with a sensitivity of 87.5%, 100% and 62.5%, and specificity of 65.9%, 72.7% and 79.5%, respectively. We identified A2MG (below 175.5 mg/dL) as an independent predictor of CLAD (hazard ratio 11.5, 95% CI (1.5–91.3), p<0.021). Our findings suggest that profiles of certain APPs may help to predict the development of lung dysfunction at the very early stages after transplantation. Dove 2020-11-30 /pmc/articles/PMC7721309/ /pubmed/33299339 http://dx.doi.org/10.2147/JIR.S272662 Text en © 2020 Janciauskiene et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Janciauskiene, Sabina Royer, Pierre-Joseph Fuge, Jan Wrenger, Sabine Chorostowska-Wynimko, Joanna Falk, Christine Welte, Tobias Reynaud-Gaubert, Martine Roux, Antoine Tissot, Adrien Magnan, Antoine Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients |
title | Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients |
title_full | Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients |
title_fullStr | Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients |
title_full_unstemmed | Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients |
title_short | Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients |
title_sort | plasma acute phase proteins as predictors of chronic lung allograft dysfunction in lung transplant recipients |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721309/ https://www.ncbi.nlm.nih.gov/pubmed/33299339 http://dx.doi.org/10.2147/JIR.S272662 |
work_keys_str_mv | AT janciauskienesabina plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT royerpierrejoseph plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT fugejan plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT wrengersabine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT chorostowskawynimkojoanna plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT falkchristine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT weltetobias plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT reynaudgaubertmartine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT rouxantoine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT tissotadrien plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients AT magnanantoine plasmaacutephaseproteinsaspredictorsofchroniclungallograftdysfunctioninlungtransplantrecipients |